


BAUSCH+LOMB



LUMIFY® Redness Reliever Eye Drops

An Advance in Redness Reduction:
Brimonidine Tartrate 0.025%



LUMIFY is a trademark of Bausch & Lomb Incorporated or its affiliates.
© 2021 Bausch & Lomb Incorporated or its affiliates. LUM.0205.USA.21

Disclosures



Dr. Toyos is a paid speaker presenting on behalf of Bausch + Lomb.



Bausch + Lomb is the sponsor of this program and event.



The content of this promotional slide deck and program was developed by Bausch + and is consistent with FDA and other applicable guidelines.



This is not a continuing medical education (CME) or continuing education (CE) event, and no CME or CE credit will be provided.

Agenda

- **Rationale for Development**

- **Brief History of Brimonidine**

- **Product Profile**

- **Mechanism of Action**

- **US Clinical Development Program**
 - Phase 2
 - Phase 3 (BL861)
 - Phase 3 Safety Study (BL862)

- **Summary**

Rationale for Development of LUMIFY® Redness Reliever Eye Drops

Historically, OTC vasoconstrictors are α 1- or mixed α 1-/ α 2-adrenergic receptor (α -AR) agonists

- Selective α 1-AR agonists (phenylephrine, tetrahydrozoline)
- Mixed α 1/ α 2-AR agonists (naphazoline, oxymetazoline)
- Long-term use was generally restricted by tachyphylaxis, rebound redness, mydriasis and systemic adverse events (e.g. somnolence, dizziness)¹⁻⁴

α 1-ARs predominantly expressed in arteries vs. α 2-ARs in veins^{5,6}

- Tachyphylaxis associated with internalization/downregulation of α 1-ARs
- Rebound redness associated with vasoconstrictor-induced tissue ischemia

1. Spector SL, Raizman MB. *J Allergy Clin Immunol*. 1994;94:134-6. 2. Tappeiner C et al. *Eur J Ophthalmol*. 2009;19:129-132. 3. Vaidyanathan S et al. *Am J Respir Critical Care Med*. 2008;177:149-53. 4. Soparkar CN et al. *Arch Ophthalmol*. 1997;115:34-8. 5. Corboz et al. *Pulm Pharmacol Ther*. 2008;21:449-54. 6. Fratelli M, De Blasi A. *FEBS Lett*. 1987;212(1):149-53.

Brief History of Brimonidine



Brimonidine Tartrate is a selective α 2-AR agonist



Used topically as Rx ophthalmic at concentrations >0.1% for lowering IOP in patients with OAG or OHT¹

- Acts on iris-ciliary body α 2-ARs to lower IOP by reducing aqueous humor production²
- Also increases uveoscleral outflow over longer-term³



Used topically as Rx dermal at 0.33% (gel) for treatment of persistent facial erythema rosacea⁴



Dose-dependent effect on conjunctival blood vessels

- High doses → associated with hyperemia⁵
- Low doses → associated with conjunctival 'whitening or blanching'⁶

1. Rahman MQ et al. *Expert Opin Drug Saf.* 2010;9:483-92. Potter DE et al. *J Ocul Pharmacol.* 1990;6:251-7. 3. Toris CB et al. *Arch Ophthalmol.* 1995;113:1514-7. 4. Fowler J Jr et al. *J Dermatol.* 2013;12:650-6. 5. Melamed S, David R. *Clin Ther* 2000;22:103-11. 6. Data on file.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.